Slide 11BeAPP pharma.be, Brussels Nov 23 12 Be (pharmaco)vigilant! Important changes in the PV-legislation 23-11-2012 Slide 2 Does a safe environment guaranty safety? M.Sangeleer,…

IT-Consulting Life Science From the IDMP Readiness Assessment and Gap Analysis to the selection of an IDMP Solution Architecture Dr. Dieter Schlaps IT-Consulting Life Science…

1. 2012–2013 Annual Report of the HMA Strategy 2. 2 Postal address: Heads of Medicines Agencies Permanent Secretariat, c/o Irish Medicines Board, Earlsfort Centre, Earlsfort…

Pharmacovigilance system in Ukraine: history, results, objectives Formation of pharmacovigilance in Ukraine 1992… Setting up Pharmacological and Pharmacopoeial Committees,…

PowerPoint Presentation Update Report on the activity of the HMA Task Force on Resources for MRP and DCP Christer Backman 1 Based on: Meeting of the HMA Task Force on Resources…

K E E P I N G Y O U t H E t O P R A N E W s L E t t E R – K E E P I N g M E M B E R s I N t O u C H JAN 2012 2012 is likely to be a challenging, memorable and possibly…

1. Pharmacovigilance and Transparency Wouter Pors 2. Pharmacovigilance Seminar Page 2 © Bird & Bird LLP 2013 Table of contents Introduction Section 1 – Transparency…